| __timestamp | Dynavax Technologies Corporation | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 16758000 |
| Thursday, January 1, 2015 | 22180000 | 17793000 |
| Friday, January 1, 2016 | 37257000 | 18761000 |
| Sunday, January 1, 2017 | 27367000 | 19287000 |
| Monday, January 1, 2018 | 64770000 | 18707000 |
| Tuesday, January 1, 2019 | 74986000 | 20893000 |
| Wednesday, January 1, 2020 | 79256000 | 25678000 |
| Friday, January 1, 2021 | 100156000 | 29665000 |
| Saturday, January 1, 2022 | 131408000 | 43628000 |
| Sunday, January 1, 2023 | 152946000 | 69135000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Geron Corporation and Dynavax Technologies Corporation, from 2014 to 2023. Over this period, Dynavax has seen a staggering 760% increase in SG&A expenses, reflecting its aggressive expansion and marketing strategies. In contrast, Geron Corporation's SG&A expenses have grown by approximately 310%, indicating a more conservative approach. Notably, in 2023, Dynavax's expenses were more than double those of Geron, highlighting differing strategic priorities. Understanding these trends provides valuable insights into how each company allocates resources to drive growth and manage operational costs. As the biotech landscape evolves, these financial strategies will play a pivotal role in shaping their future trajectories.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: Biogen Inc. vs Dynavax Technologies Corporation
Exelixis, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Geron Corporation
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation
Xenon Pharmaceuticals Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Xenon Pharmaceuticals Inc. vs Geron Corporation
Who Optimizes SG&A Costs Better? Vericel Corporation or Geron Corporation
Cost Management Insights: SG&A Expenses for HUTCHMED (China) Limited and Geron Corporation
Cost Management Insights: SG&A Expenses for Protagonist Therapeutics, Inc. and Geron Corporation
Comparing SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
Breaking Down SG&A Expenses: Dynavax Technologies Corporation vs Xencor, Inc.